| Literature DB >> 28455089 |
Miranda E Orr1, A Campbell Sullivan2, Bess Frost3.
Abstract
There are currently no disease-modifying therapies for the treatment of tauopathies, a group of progressive neurodegenerative disorders that are pathologically defined by the presence of tau protein aggregates in the brain. Current challenges for the treatment of tauopathies include the inability to diagnose early and to confidently discriminate between distinct tauopathies in patients, alongside an incomplete understanding of the cellular mechanisms involved in pathogenic tau-induced neuronal death and dysfunction. In this review, we describe current diagnostic and therapeutic strategies, known drivers of pathogenic tau formation, recent contributions to our current mechanistic understanding of how pathogenic tau induces neuronal death, and potential diagnostic and therapeutic approaches.Entities:
Keywords: Alzheimer’s disease; metabolic syndrome; neurodegeneration; tau; tauopathy; traumatic brain injury
Mesh:
Year: 2017 PMID: 28455089 PMCID: PMC5476494 DOI: 10.1016/j.tips.2017.03.011
Source DB: PubMed Journal: Trends Pharmacol Sci ISSN: 0165-6147 Impact factor: 14.819